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A B S T R A C T
Most patients with metastatic germ-cell cancer (GCC) can be cured by cisplatin-based combination che-
motherapy. Yet, about 10–15% of metastatic GCC patients will eventually die of their disease. This narrative
review focuses on treatment options when cure is no longer realistic.
Introduction
Germ-cell cancers (GCC) are a unique example of a curable malig-
nant disease [1]. Therefore, palliative treatment is rarely being dis-
cussed. Yet, 10–15% of metastatic patients will fail first as well as
subsequent lines of platinum-based treatments and eventually die of
their disease [2]. Palliative treatment of patients with GCC remains
challenging with little high-level evidence to support decision making
in this situation.
Who is “palliative” among GCC patients?
There is good evidence that subsets of patients with multiple re-
lapses, and, to a lesser extent, patients with primary cisplatin-refractory
disease may still be cured by conventional-dose (CDCT), high-dose
chemotherapy (HDCT) and/or desperation surgery delivered as first,
second or subsequent salvage treatment [2–8]. Therefore, patients will
usually have had multiple lines of chemotherapy including HDCT be-
fore being considered palliative. The same applies to patients unfit for
HDCT failing three or more lines of CDCT [2,9]. The majority of pa-
tients will have received modern type cisplatin- and ifosfamide-based
salvage regimens such as cisplatin, ifosfamide and vinblastine (VeIP),
etoposide (VIP) or paclitaxel (TIP) [2,9]. Desperation surgery might still
salvage individual patients of these two cohorts [5–7]. However, if
desperation surgery cannot successfully be performed, patients failing
HDCT or three or more lines of CDCT face little or no realistic hope for
cure. Therefore, a palliative treatment population can be defined as
patients failing salvage HDCT or patients unfit for HDCT who fail three
or more lines of CDCT in whom desperation surgery cannot be suc-
cessfully be performed. Rare exceptions to this definition may occur.
With respect to the many early clinical trials investigating different
systemic treatment approaches for refractory GCC patients, life-exten-
sion remains the primary goal for the majority of patients. As reported
in the following sections, responses are generally short-lived, which is
why alleviation of pain and other symptoms to enhance the patients’
quality-of-life is also desired. However, quality-of-life was not routinely
assessed as a trial end point in the majority of available studies and has
to be considered individually as a main goal, whichever treatment is
being chosen. To provide a better understanding of the efficacy and
toxicities associated with palliative treatments, common adverse events
for the different treatment options are mentioned in the tables.
Single agent chemotherapy
Single agent activity has been reported for paclitaxel [10–14],
gemcitabine [15,16], oxaliplatin [17,18], oral etoposide [19], ifosfa-
mide [20], and oral temozolomide [21] mainly in small phase I/II trials
in patients with cisplatin-refractory disease. Responses were mainly
partial remissions or disease stabilizations. However, sequential single
agent treatment is an appropriate option in addition to best-supportive-
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care in the palliative setting of patients with a poor performance status
asking for further active treatment in order to avoid the more frequent
side-effects of combination chemotherapy. Table 1 provides an over-
view of single-agent chemotherapy regimens.
Combination chemotherapy
Combinations of drugs with single-agent activity result in higher
response rates compared to using single-agent treatment alone. The
triple combination of gemcitabine, oxaliplatin and paclitaxel (GOP)
reported the highest response rates so far with more than 50% objective
responses and even few long-term remissions (Table 2) [22–25].
Doublet combinations of these drugs may also provide favorable re-
sponses ranging from 4% to 46% (Table 3) [26–31]. Other doublets
include cisplatin, plus epirubicin [32] or irinotecan [33], or oxaliplatin
together with the VEGF-targeted antibody bevacizumab [34] or again
irinotecan [35]. Other triple combination regimens comprise of pacli-
taxel, cisplatin and gemcitabine (TPG) (ORR 49%) [36], or oxaliplatin,
irinotecan and paclitaxel (IPO) followed by one cycle of topotecan-
based HDCT (ORR 49%) [37]. Recently, clinical activity and good tol-
erability of the combination of etoposide, methotrexate and actino-
mycin D, alternating with cyclophosphamide and vincristine (EMA/
CO), as established for female gestational trophoblastic disease, has
been reported in patients with refractory GCC and elevated levels of
human chorionic gonadotrophin [38] (Table 2).
Taken together, combination chemotherapy seems to be the most
promising palliative approach in medically fit patients with a good
performance status in whom the toxicities of a doublet or a triple
combination seem acceptable. Direct comparisons of combination
treatments have not been published, and none of the regimens have
proven unequivocal superiority.
Targeted treatments and immunotherapy
Investigational agents include tyrosine kinase inhibitors, i.e. suni-
tinib [39,40], sorafenib [41], imatinib [42], tivantinib [43] and pazo-
panib [44] as well as anti-angiogenic agents, i.e. thalidomide [45] and
lenalidomide [46], and the mTOR inhibitor everolimus [47] amongst
many others (Table 4). However, apart from single case reports, all
these agents failed to induce clinically meaningful responses in un-
selected patient cohorts [48]. Similarly, antibody-drug conjugate
brentuximab-vedotin was investigated in CD30-positive, refractory GCC
patients. Some responses were observed but tended to be short-lived
[49,50]. Thus, the results of investigational agents are conflicting, and
at present these drugs have no established role in the palliative treat-
ment setting of GCC.
Immunomodulatory treatment with immune checkpoint inhibitors
active against the programmed- cell death receptor (PD-1) or itś ligand
(PD-L1) are currently being investigated also in refractory GCC as many
tumors were shown to express PD-L1 [51]. However, application of the
PD-1-directed monoclonal antibody pembrolizumab failed to induce
clinically meaningful responses in a phase II trial enrolling 12 patients,
which was terminated prematurely [52]. In another phase II trial, the
anti-PD-L1 antibody Durvalumab alone yielded no responses among 9
GCC patients, whereas the combination with the CTLA-4 antibody tre-
melimumab achieved clinical responses in 2 out of 9 heavily pretreated
GCC patients [53]. Other immune checkpoint inhibitors are currently
under investigation, i.e. single agent treatment with the PD-L1 antibody
Table 1
Single agent regimens.
Drug Schedule N Patients Previous
HDCT
ORR Duration of benefit for responders
(measure, median, range) [months]
Relevant toxicities ≥grade 3 Ref
Gemcitabine 1000mg/m2 iv. d1,8,15 q3w 31 71% 19% TTF, 4+ (2–9+) Granulocytopenia 13%
Thrombocytopenia 22%
15
1200mg/m2 iv. d1,8,15 q3w 20 55% 15% PFS, n.r. (2–6) Neutropenia 10% 16
Thrombocytopenia 30%
Nausea 5%
Oxaliplatin 60mg/m2 iv. d1,8,15 q3w 16 78% 6% PFS, n.r. (2–8) Granulocytopenia 9% 17
130mg/m2 iv. d1 q2w 16 19% Thrombocytopenia 16%
Nausea/vomiting 6%
Neurotoxicity 3%
130mg/m2 iv. d1 q3w 8 NR 25% PFS, n.r. n.r. 18
Paclitaxel 135–310mg/m2 iv. d1 q3w 10 NR 20% DOR, n.r. (3–5) Granulocytopenia 90% 14
Infection 10%
170mg/m2 iv. d1 q3w 18 16% 11% PFS, n.r. (1.5–2) Granulocytopenia 67% 13
Anemia 7%
Neutropenic fever 17%
Neurotoxicity 13%
225mg/m2 iv. d1 q3w 24 50% 25% DOR, 8+ (3–16+) Granulocytopenia 50% 11
Thrombocytopenia 16%
Severe infections 12%
Neurotoxicity ≥°II 27%
Mucositis °II/III 16%
250mg/m2 iv. d1 q3w 15 13% 13% DOR, n.r. (9–10 weeks) Neutropenia 87% 12
Thrombocytopenia 73%
Peripheral neuropathy °II/III 53%
250mg/m2 iv. d1 q3w 31 16% 26% n.r. Mainly hematologic 10
Neurotoxicity °III 19%
Mucositis °II/III 16%
Liver function test > 5xULN 10%
Ifosfamide 2000mg/m2 iv. d1-5 q3w 30 NR 23% DOR, 3.5 (2–5.5) Neutropenia 52% 20
Thrombocytopenia 20%
Nausea/vomiting 43%
Oral Etoposide 50mg/m2 po. d1-14 q3w 21 29% 14% n.r. Granulocytopenia 36% 19
Febrile granulocytopenia 23%
Oral Temozolomide 150–200mg/m2 po. d1-5 q4w 20 40% 10% DOR, 1.5 (3.5–9) Thrombocytopenia 10% 21
Anemia 5%
DOR, duration of response; PFS, progression-free survival; TTF, time to treatment failure; n.r., not reported.
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Atezolizumab (NCT02458638), or the PD-1 antibody Nivolumab
(NCT02832167) in phase II basket trials. Moreover, combined treat-
ment approaches, such as the anti-PD-1 antibody Nivolumab plus anti-
CTLA-4 antibody Ipilimumab, are also currently being evaluated
(NCT02834013).
Choosing the right treatment for the right patient
Finding the right treatment for the right patient at the right time is
obviously key to any palliative strategy in GCC patients. A formal
comparison of available palliative regimens was not attempted in this
review, as cohorts of published series are notoriously small and pre-
treatments too heterogeneous to allow a meaningful approach.
However, the large number of small studies indicates the lack of un-
equivocal superiority of any given regimen. Many palliative patients
will receive sequential lines of treatments often switching from a
combination to a single-agent regimen until available options are ex-
hausted. An algorithm to support treatment selection is given in Fig. 1.
Challenging scenarios in palliative GCC patients
Brain metastases
Palliative patients with GCC and brain metastases should still re-
ceive radiotherapy for symptom control, delivered either as stereotactic
or total brain irradiation depending on the number and location of the
metastases as well as the local availability of the respective techniques.
Patients who are “fit” for chemotherapy may be treated with multi-
modality strategies of chemotherapy and irradiation. In the palliative
setting neurosurgery is rarely indicated [54].
Bone metastases
Patients suffering metastatic bone disease may undergo multimodal
treatment including chemotherapy and radiotherapy to alleviate ske-
letal symptoms, if a limited number of symptomatic bone metastases
are present. The use of anti-resorptive agents, e.g. bisphosphonates or
RANKL-inhibitors can be considered, although data on their use in GCC
patients is lacking [55].
Peripheral neuropathy
The majority of palliative GCC patients experience peripheral neu-
ropathy as a result of exposure to cisplatin, to taxanes or to HDCT.
Treatment options and high-level evidence are limited, but the use of
co-analgesic medication, e.g. the antidepressants duloxetine, ami-
tryptiline or venlafaxine and/or the anticonvulsants gabapentin or
pregabalin may alleviate symptoms [56]. Often peripheral neuropathy
will limit or prohibit the further use of cisplatin, oxalipatin or the
taxanes.
Early integration of palliative care and psychosocial support
Similar to patients suffering from other malignancies, palliative
patients with GCC may benefit from early integration of a specialized
palliative care team in order to professionally identify and treat many of
the additional symptoms and needs common to palliative cancer pa-
tients [57]. Particularly, the young age of patients with GCC increases
their vulnerability for psychological distress. Studies have emphasized a
strong correlation between young age and higher levels of anxiety and
depression among patients and their relatives [57]. Therefore, psy-
chological support must be an integral part of any palliative strategy in
GCC patients.
Table 2
Triple-drug regimens.
Drug Schedule Patients Previous HDCT ORR Duration of benefit for responders
(measure, median, range) [months]
Relevant toxicities ≥grade 3 Ref
Gemcitabine 800mg/mb iv. d1&8 q3w 41 78% 51% PFS, 3 (1–17+) Granulocytopenia 15% 24
Oxaliplatin 130mg/mb iv. d1 q3w Anemia 7%
Paclitaxel 80mg/mb iv. d1&8 q3w Thrombocytopenia 49%
Neurotoxicity 2%
Nausea/Emesis 2%
Diarrhea 2%
Gemcitabine 800mg/mb iv. d1&8 q2w 30 20% 31% PFS, 6.5 (95%CI, 3.2–27.5) Neutropenia 17% 25
Oxaliplatin 100–125mg/mb iv. d1 q2w Febrile Neutropenia 7%
Paclitaxel 170mg/mb iv. d1 q2w Gastrointestinal °II/III 12%
Neuropathy 5%
Cisplatin 50mg/mb iv. d1&8 q3w 75 13% DCR 67% PFS, 5 (95%CI, 4–8) Anemia 28% 36
Neutropenia 29%
Gemcitabine 800mg/mb iv. d1&8 q3w Febrile Neutropenia 5%
Paclitaxel 80mg/mb iv. d1&8 q3w Thrombocytopenia 40%
Ototoxicity 4%
Oxaliplatin 100mg/mb iv. d1 q3w 43 0% (74% sub-
sequent HDCT)
49% 2-year PFS 21%, (median n.r.) Neutropenia 33% 37
Irinotecan 200mg/mb iv. d1 q3w Thrombocytopenia 16%
Paclitaxel 80mg/mb iv. d1,8,15 q3w Neuropathy 2%
Nause/Emesis 4%
Diarrhea 12%
Etoposide 100mg/mb iv. d1&2 q2w 41 39% 29% PFS, 3 (95%CI, 2–4) Hematologic 39% 38
Methotrexatea 300mg/mb iv. d1 q2w
Folinic acidb 15mg×4 iv./po. d2&3 q2w
Actinomycin D 0.5mg/mb iv. d1&2 q2w
Vincristine 1mg/mb iv. d8 q2w
Cyclophosphamide 600mg/mb iv. d8 q2w
DCR, disease control rate (complete+ partial remissions+ stable disease); DOR, duration of response; PFS, progression-free survival; TTF, time to treatment failure,
HDCT, high-dose chemotherapy.
a Methotexate given as continuous infusion over 12 h.
b Folinic acid started 24 h after methotraxate for 4 doses every 12 h.
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Conclusion
Guidance of treatment and care of refractory GCC patients in the
palliative setting is challenging and emotionally demanding. Although
some cytotoxic agents have shown efficacy either as single agents or as
part of drug combinations, survival is limited and durable remissions
are rare. The most difficult decision is when to stop cancer-directed
treatments altogether and switch to best-supportive care alone. On the
technical side, we suggest as one cornerstone of care close contact with
an expert GCC center that cares for such patients regularly. Locally,
early integration of specialized palliative care as outlined by the
American Society of Oncology [58] is the second cornerstone that
supports symptom control and alleviates suffering for all parties in-
volved.
Table 3
Doublet regimens.
Drug Schedule Patients Previous
HDCT
ORR Duration of benefit for responders (measure,
median, range) [months]
Relevant toxicities ≥grade 3 Ref
Gemcitabine 1000mg/m2 iv. d1&8 q3w 35 89% 46% DFS, n.r. (2–16+) Leukocytopenia 54% 26
Oxaliplatin 130mg/m2 iv. d1 q3w Thrombocytopenia 48%
Anemia 11%
Febrile Neutropenia 9%
Treatment-related death 3%
Neurotoxicity 9%
Nausea/Emesis 16%
Diarrhea 6%
Gemcitabine 1000mg/m2 iv. d1&8 q3w 28 14% 32% DFS, n.r. (2–28+) Neutropenia 62% 27
Oxaliplatin 130mg/m2 iv. d1 q3w Febrile Neutropenia 10%
Thrombocytopenia 41%
Anemia 21%
Neurotoxicity 10%
Nausea/Emesis 27%
Fatigue 17%
Gemcitabine 1250mg/m2 iv. d1&8 q3w 18 22% 17% DFS, n.r. (18+ - 44+) Neutropenia 39% 28
Oxaliplatin 130mg/m2 iv. d1 q3w Thrombocytopenia 22%
Anemia 11%
Peripheral Neuropathy 17%
Asthenia 11%
Nausea/Vomiting 5%
Paclitaxel 175mg/m2 iv. d1 q3w 26 19% 4% TTP, 1.4 (95%CI 0–14.8) Neutropenia 30% 29
Oxaliplatin 130mg/m2 iv. d1 q3w Thrombocytopenia 4%
Anemia 12%
Neuropathy 1%
Nausea/Emesis 8%
Fatigue 4%
Bevacizumab 10mg/kg iv. d1&8 q3w 24 54% 29% DOR, 6 (4–22) Peripheral neuropathy 34
Oxaliplatin 85mg/m2 iv. d1 q2w Hypertension
Seizuress
Deep vein thrombosi
Oxaliplatin 85mg/m2 iv. d1&15 q4w 18 0 39% DFS, n.r. (2–19+) Neutropenia 17% 36
Irinotecan 80mg/m2 iv. d1,8,15 q4w Thrombocytopenia 17%
Anemia 12%
Neurotoxicity 11%
Nausea/Emesis 28%
Diarrhea 22%
Mucositis 11%
Cisplatin 20mg/m2 iv. d1-5 q3w 30 13% 57% NED, n.r. (n.r. – 48+) Neutropenia 13% 32
Epirubicin 90mg/m2 iv. d1 q3w Febrile Neutropenia 3%
Thormbocytopenia 7%
Anemia 17%
Neuropathy 7%
Nausea/Vomiting 27%
Diarrhea 3%
Nephrotoxicity 7%
Cisplatin 20mg/m2 iv. d1-5 q4w 11 27% 45% DOR, n.r. (12+–140+) Neutropenia 18% 33
Irinotecan 100–150mg/m2 iv. d1&15 q4w Thrombocytopenia 17%
Anemia 14%
Nausea/Vomiting 8%
Diarrhea 5%
Paclitaxel 110mg/m2 iv. d1,8,15 q4w 28 36% 21% DOR, n.r. (2–25+) Neutropenia 54% 30
Gemcitabine 1000mg/m2 iv. d1,8,15 q4w Febrile Neutropenia 4%
Thrombocytopenia 32%
Anemia 11%
Neuropathy 4%
Nausea/Emesis 8%
Fatigue 8%
Paclitaxel 100mg/m2 iv. d1,8,15 q4w 32 100% 31% NED, n.r. (22+–54+) n.r. 31
Gemcitabine 1000mg/m2 iv. d1,8,15 q4w
DFS, disease-free survival; DOR, duration of response; NED, no evidence of disease; PFS, progression-free survival; TTF, time to treatment failure; n.r., not reported.
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